| Vismodegib studied in …STUDIED_INderived10 of 75show all (up to 200) |
|---|
| → studied in | NCT06616623Phase 1 · suspended Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer · 75 trials list this drug (15 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00878163Phase 1 · active not recruiting GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery · 75 trials list this drug (15 active) | — | — | Adult Solid Neoplasm,Pancreatic Neoplasm,Pancreatic Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02523014Phase 2 · recruiting Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas · 75 trials list this drug (15 active) | — | — | Meningioma,Intracranial Meningioma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02465060Phase 2 · active not recruiting Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) · 75 trials list this drug (15 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm,Lymphoma,Malignant Solid Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01267955Phase 2 · active not recruiting Vismodegib in Treating Patients With Advanced Chondrosarcomas · 75 trials list this drug (15 active) | — | — | Chondrosarcoma,Clear Cell Chondrosarcoma,Dedifferentiated Chondrosarcoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00887159Phase 2 · completed A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage · 75 trials list this drug (15 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05538091Phase 2 · recruiting Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer · 75 trials list this drug (15 active) | — | — | Platinum-Resistant Primary Peritoneal Carcinoma,Platinum-Resistant Fallopian Tube Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06357988Phase 2 · active not recruiting Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T) · 75 trials list this drug (15 active) | — | — | Hematopoietic and Lymphatic System Neoplasm,Lymphoma,Malignant Solid Neoplasm+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00833417Phase 2 · completed A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) in Patients With Advanced Basal Cell Carcinoma · 75 trials list this drug (15 active) | — | — | Basal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00959647Phase 2 · completed A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study · 75 trials list this drug (15 active) | — | — | Basal Cell Carcinoma,Malignant Ovarian Neoplasm,Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |